Compare EPR Properties (EPR) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Cassava Sciences Inc — how do they compare? EPR Properties trades at $59.8 (market cap $4.58B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: EPR Properties is far larger — about 95.9× Cassava Sciences Inc's market cap, and EPR Properties pays a 6.22% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| EPR | FLNA | |
|---|---|---|
Market Cap | $4.58B | $47.75M |
Sector | Real Estate | Health |
52-Week High | $64.32 | $4.64 |
52-Week Low | $48.71 | $0.87 |
Enterprise Value | $8.09B | -$34.93M |
Dividend Yield | 6.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
